These 4 Stocks are in Big Danger | Trump Tariff Attack Pharma Sector

Finance-focused summary (markets/investing context)

• Event driving the move: A U.S. policy/tariff tweet attributed to Donald Trump triggered a broad selloff in India’s pharma sector and pressured broader Indian indices. The host notes Nifty fell and that pharma momentum was “destroyed.”
• Policy described (timeline + tariff path):
  • Effective 1 Aug 2026: 0% tariff for certain imported generic drugs.
  • After 2 years (framed as 2028): 100% tariff for one year.
  • Then (2029): 200% tariff.
• Market interpretation by host: The host argues the market was pricing in forward outcomes (including a 2-year estimate), creating a potential “buy-the-dip” setup. However, the host warns the bigger danger is if tariffs expand beyond simple generics (into more complex segments).

---

Instruments / tickers / companies mentioned

Index / market

• Nifty
• Nifty Pharma (sector)

Indian pharma / healthcare companies

• Sun Pharma (Sunfarma)
• Torrent
• Mankind
• Alkem
• JB Chemicals / JB Pharm / JB Pharmac (name appears variably)
• EIS Life Sciences (spelled “EIS”)
• Aurobindo Pharma (Orurobindo / Aurobindo)
• Gland Pharma
• Granules India (Granules)
• Dr. Reddy’s Laboratories (referred to as “Doctor ready / Dr. Eddie”)
• Glenmark
• Lupin
• Divis / Divi’s (Divis Laboratories implied)
• KaplanPoint (appears as “Kaplan Point”; context: injectables)
• Zydus (mentioned in lobbying context)
• Apollo Hospitals
• AshtraDM / Astrad DM (unclear exact spelling)

U.S. / deal / entities

• Orion / Oraon (referred to as “Oraon/Oraon/Oraon”-type variants): tied to a $1B deal acquisition by Sun Pharma; linked in the narrative to a biosimilars landscape.
• Organon (referred to in a “Sun Pharma Organon acquisition” narrative): host cites an $11.75B deal; subtitles may have conflated/garbled the deal name.

Currencies / macro

• INR (host references ~96.5)

Sectors referenced

• Pharma (generics vs complex generics / biosimilars / CDMO / specialty API)
• Hospitals / healthcare
• Other macro sectors (IT, banking) as broader India drivers influencing FII behavior

---

Key numbers & performance / risk metrics mentioned

Tariff impact path (as stated by host)

• 0% starting 1 Aug 2026
• 100% in 2028 (host framing)
• 200% in 2029 (host framing)

Export / industry statistics

• Indian pharma exports: ~$9.7B (labeled “FI25”)
• 38% of global pharma exports: ~$25.8B (as stated)
• Sector growth: 9.43% (noted as stated; subtitles later include a formatting artifact “43%”)
• Pharma contribution to GDP: ~1.72%

FX / valuation narrative

• INR ~96.5
• Host claims pharma benefits from USD pricing, tying INR strength to relief/benefit.

Company-specific exposure (explicit risk table content)

• Granules India: 70–74% of revenue from the US → risk level: critical
• Gland Pharma: ~53% US revenue
• Aurobindo Pharma: ~49% US revenue
• Dr. Reddy’s: ~45% US revenue
• Glenmark: ~25% US revenue
• Sun Pharma: ~33–25% US revenue (subtitles inconsistent)
• Lupin: ~25% US revenue
• Granules management guidance:
  • 20–25% cost increase if tariff materializes
  • “Extremely difficult” to pass through pricing due to heavy competition

Prescription / income impact (host claims)

• 90% of U.S. generic prescriptions are imported (host claim)
• Indian generics filled 47% of U.S. generic prescriptions as of 2022 (host claim)
• Americans saved $219B and ~$1.3T over the past decade (host claims)

Market sizing

• Biosimilars market: $300B (as stated “as of today”)

Deal / capacity facts cited

• Aurobindo (East Windsor, New Jersey):
  • 8 lakh 20,000 ft² campus
  • New facility: 1 lakh 70,000 ft²
  • “Ribbon cut Sept 2025” for OTC + injectable manufacturing
• Aurobindo (another facility):
  • North Carolina: 40,000 ft²
  • Pilot plant for CGMP specialty products
• Lupin:
  • Plant in Coral Springs, Florida
  • $250M investment
  • 1,200 jobs
• Sun Pharma:
  • U.S. acquisition described as $1B (biosimilars narrative)
  • Separate mention of $11.75B (likely tied to the Organon/biosimilars storyline; subtitles may have garbled deal naming)

Valuation approach mentioned

• Interest in stocks with lower P/E and lower price-to-sales (no exact multiples quoted)

---

Framework / strategy methodology explicitly described

Host’s investing approach (“buy on dip”)

The host treats the tariff-driven selloff as a mispricing opportunity because:

• No tariff impact until 2028 (per host’s timeline), so the market may be overreacting to forward estimates.
• Some subsectors (e.g., CDMO, API suppliers to tariff-exempt innovator clients) are argued to be less exposed.

“Real risk” framework (as described):

• Base case: tariffs apply to normal generics → limited damage expected.
• Key downside trigger: if tariffs expand into complex generics and/or injectables → broader sector hit.

Segment-by-segment mapping (risk differentiation)

• Domestic formulation-focused firms (less direct tariff exposure but sentiment drag persists):
  • Torrent, Mankind, Alkem, JB (and others)
• CDMO firms (argued to supply innovator/large global clients):
  • Laurus Labs, Divis (API/supply angle)
• Innovator / specialty portfolio firms:
  • Sun Pharma (specialty + U.S. acquisitions into biosimilars)
• Pure-play generics with high U.S. revenue (highest risk):
  • Granules India, Aurobindo, Gland Pharma, Dr. Reddy’s, Glenmark
  • Risk tied to % of US revenue

---

Recommendations / cautions / disclosures

Recommendation (explicitly stated)

• “Buy on dip” strategy
• The host calls it a “beautiful mispriced opportunity.”
• Even if the stock falls further, the thesis is argued to remain attractive (per host commentary).

Critical caution (explicit)

• The key risk is tariffs expanding beyond normal generics into complex generics and injectables.

Stated disclaimer

• The subtitles provided do not include a clear “not financial advice” line.

---

Presenter / sources mentioned

• Presenter / host: Shashang Gurapa
  • There is a reference to a “boss” as a co-host/participant, but no additional named credentials.
• Named sources / quotes:
  • Vishal Mananda of Systematic Institutional Equities (quoted regarding inflationary impact / lack of U.S. infrastructure)
  • Dilip Sanangi of Sun Pharma (stated that if tariffs are imposed, they will pass on costs to customers)
• Named industry / lobbying group:
  • IPA (implied as an industry association lobbying for tariff exemptions; full form not provided in subtitles)